• Je něco špatně v tomto záznamu ?

International reference analysis of outcomes in adults with B-precursor Ph-negative relapsed/refractory acute lymphoblastic leukemia

N. Gökbuget, H. Dombret, JM. Ribera, AK. Fielding, A. Advani, R. Bassan, V. Chia, M. Doubek, S. Giebel, D. Hoelzer, N. Ifrah, A. Katz, M. Kelsh, G. Martinelli, M. Morgades, S. O'Brien, JM. Rowe, J. Stieglmaier, M. Wadleigh, H. Kantarjian,

. 2016 ; 101 (12) : 1524-1533. [pub] 20160901

Jazyk angličtina Země Itálie

Typ dokumentu časopisecké články, multicentrická studie

Perzistentní odkaz   https://www.medvik.cz/link/bmc17031462

Adults with relapsed/refractory acute lymphoblastic leukemia have an unfavourable prognosis, which is influenced by disease and patient characteristics. To further evaluate these characteristics, a retrospective analysis of 1,706 adult patients with Ph-negative relapsed/refractory B-precursor acute lymphoblastic leukemia diagnosed between 1990-2013 was conducted using data reflecting the standard of care from 11 study groups and large centers in Europe and the United States. Outcomes included complete remission, overall survival, and realization of stem cell transplantation after salvage treatment. The overall complete remission rate after first salvage was 40%, ranging from 35%-41% across disease status categories (primary refractory, relapsed with or without prior transplant), and was lower after second (21%) and third or greater (11%) salvage. The overall complete remission rate was higher for patients diagnosed from 2005 onward (45%, 95% CI: 39%-50%). One- and three-year survival rates after first, second, and third or greater salvage were 26% and 11%, 18% and 6%, and 15% and 4%, respectively, and rates were 2%-5% higher among patients diagnosed from 2005. Prognostic factors included younger age, longer duration of first remission, and lower white blood cell counts at primary diagnosis. This large dataset can provide detailed reference outcomes for patients with relapsed/refractory Ph-negative B-precursor acute lymphoblastic leukemia. clinicaltrials.gov identifier: 02003612.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc17031462
003      
CZ-PrNML
005      
20240516082424.0
007      
ta
008      
171025s2016 it f 000 0|eng||
009      
AR
024    7_
$a 10.3324/haematol.2016.144311 $2 doi
035    __
$a (PubMed)27587380
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a it
100    1_
$a Gökbuget, Nicola $u University Hospital, Goethe University, Frankfurt, Germany goekbuget@em.uni-frankfurt.de.
245    10
$a International reference analysis of outcomes in adults with B-precursor Ph-negative relapsed/refractory acute lymphoblastic leukemia / $c N. Gökbuget, H. Dombret, JM. Ribera, AK. Fielding, A. Advani, R. Bassan, V. Chia, M. Doubek, S. Giebel, D. Hoelzer, N. Ifrah, A. Katz, M. Kelsh, G. Martinelli, M. Morgades, S. O'Brien, JM. Rowe, J. Stieglmaier, M. Wadleigh, H. Kantarjian,
520    9_
$a Adults with relapsed/refractory acute lymphoblastic leukemia have an unfavourable prognosis, which is influenced by disease and patient characteristics. To further evaluate these characteristics, a retrospective analysis of 1,706 adult patients with Ph-negative relapsed/refractory B-precursor acute lymphoblastic leukemia diagnosed between 1990-2013 was conducted using data reflecting the standard of care from 11 study groups and large centers in Europe and the United States. Outcomes included complete remission, overall survival, and realization of stem cell transplantation after salvage treatment. The overall complete remission rate after first salvage was 40%, ranging from 35%-41% across disease status categories (primary refractory, relapsed with or without prior transplant), and was lower after second (21%) and third or greater (11%) salvage. The overall complete remission rate was higher for patients diagnosed from 2005 onward (45%, 95% CI: 39%-50%). One- and three-year survival rates after first, second, and third or greater salvage were 26% and 11%, 18% and 6%, and 15% and 4%, respectively, and rates were 2%-5% higher among patients diagnosed from 2005. Prognostic factors included younger age, longer duration of first remission, and lower white blood cell counts at primary diagnosis. This large dataset can provide detailed reference outcomes for patients with relapsed/refractory Ph-negative B-precursor acute lymphoblastic leukemia. clinicaltrials.gov identifier: 02003612.
650    _2
$a mladiství $7 D000293
650    _2
$a dospělí $7 D000328
650    _2
$a senioři $7 D000368
650    _2
$a senioři nad 80 let $7 D000369
650    _2
$a kombinovaná terapie $7 D003131
650    _2
$a chemorezistence $7 D019008
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a průzkumy zdravotní péče $7 D019538
650    _2
$a lidé $7 D006801
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a lidé středního věku $7 D008875
650    12
$a filadelfský chromozom $7 D010677
650    _2
$a pre-B-buněčná leukemie $x diagnóza $x genetika $x mortalita $x terapie $7 D015452
650    _2
$a prognóza $7 D011379
650    _2
$a recidiva $7 D012008
650    _2
$a indukce remise $7 D012074
650    _2
$a opakovaná terapie $7 D019233
650    _2
$a retrospektivní studie $7 D012189
650    _2
$a analýza přežití $7 D016019
650    _2
$a výsledek terapie $7 D016896
650    _2
$a mladý dospělý $7 D055815
655    _2
$a časopisecké články $7 D016428
655    _2
$a multicentrická studie $7 D016448
700    1_
$a Dombret, Hervé $u Hôpital Saint-Louis, Paris, France $7 xx0316388
700    1_
$a Ribera, Jose-Maria $u ICO-Hospital Germans Trias I Pujol, Jose Carreras Research Institute, Barcelona, Spain.
700    1_
$a Fielding, Adele K $u UCL Cancer Institute, London, UK.
700    1_
$a Advani, Anjali $u Cleveland Clinic, Ohio, USA. $7 gn_A_00001918
700    1_
$a Bassan, Renato $u UOC Ematologia, Ospedale dell'Angelo, Mestre-Venezia, Italy. $7 xx0317382
700    1_
$a Chia, Victoria $u Center for Observational Research, Amgen, USA.
700    1_
$a Doubek, Michael $u University Hospital, Brno, Czech Republic.
700    1_
$a Giebel, Sebastian $u Maria Sklodowska Curie Memorial Cancer Center and Institute of Oncology, Gliwice, Poland.
700    1_
$a Hoelzer, Dieter $u University Hospital, Goethe University, Frankfurt, Germany.
700    1_
$a Ifrah, Norbert $u Center Hospitalier Universitaire, Angers, France.
700    1_
$a Katz, Aaron $u Center for Observational Research, Amgen, USA.
700    1_
$a Kelsh, Michael $u Center for Observational Research, Amgen, USA.
700    1_
$a Martinelli, Giovanni $u Policlinico Sant'Orsola, Istituto Seragnoli, Bologna, Italy.
700    1_
$a Morgades, Mireia $u ICO-Hospital Germans Trias I Pujol, Jose Carreras Research Institute, Barcelona, Spain.
700    1_
$a O'Brien, Susan $u University of Texas, MD Anderson Cancer Center, Houston, USA.
700    1_
$a Rowe, Jacob M $u Rambam Medical Center, Haifa, Israel.
700    1_
$a Stieglmaier, Julia $u Clinical Development, Amgen, Germany.
700    1_
$a Wadleigh, Martha $u Dana Farber Cancer Institute, Boston, Massachusetts, USA.
700    1_
$a Kantarjian, Hagop $u University of Texas, MD Anderson Cancer Center, Houston, USA.
773    0_
$w MED00001963 $t Haematologica $x 1592-8721 $g Roč. 101, č. 12 (2016), s. 1524-1533
856    41
$u https://pubmed.ncbi.nlm.nih.gov/27587380 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20171025 $b ABA008
991    __
$a 20240516082419 $b ABA008
999    __
$a ok $b bmc $g 1255055 $s 992489
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2016 $b 101 $c 12 $d 1524-1533 $e 20160901 $i 1592-8721 $m Haematologica $n Haematologica $x MED00001963
LZP    __
$a Pubmed-20171025

Najít záznam

Citační ukazatele

Možnosti archivace